Methotrexate-Induced Pulmonary Fibrosis in a Patient with Rheumatoid Arthritis: A Case Report
Archives of Medical Reports · 31.03.2025 · 2 (1) · 1-3
DOI: 10.26524/amr.2025.2.1 ↗Kurz gefasst
Fallbericht in der Zeitschrift Archives of Medical Reports, online erschienen am 31.03.2025. Verfasst von Anu Sri S und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Methotrexate is a cornerstone in the treatment of rheumatoid arthritis (RA), offering immunosuppressive benefits that significantly reduce disease progression. However, rare adverse effects such as pulmonary fibrosis can be life-threatening. We report the case of a 66-year-old female with seropositive RA who developed progressive dyspnea and dry cough after 14 months of methotrexate therapy. Imaging and pulmonary function tests revealed restrictive lung disease, and high-resolution CT demonstrated interstitial changes consistent with drug-induced pulmonary fibrosis. Methotrexate was discontinued, and corticosteroid therapy was initiated, leading to partial symptomatic improvement. Clinicians must remain vigilant for methotrexate-induced pulmonary complications, particularly in patients presenting with new respiratory symptoms. Early recognition and intervention can mitigate irreversible damage.
Zitieren
APA
S, A. S., & Hagana, I. (2025). Methotrexate-Induced Pulmonary Fibrosis in a Patient with Rheumatoid Arthritis: A Case Report. Archives of Medical Reports, 2(1), 1-3. https://doi.org/10.26524/amr.2025.2.1
Vancouver
S AS, Hagana I. Methotrexate-Induced Pulmonary Fibrosis in a Patient with Rheumatoid Arthritis: A Case Report. Archives of Medical Reports. 2025;2(1):1-3. doi:10.26524/amr.2025.2.1
BibTeX
@article{S2025,
author = {S, Anu Sri and Hagana, Iman},
title = {Methotrexate-Induced Pulmonary Fibrosis in a Patient with Rheumatoid Arthritis: A Case Report},
journal = {Archives of Medical Reports},
year = {2025},
volume = {2},
number = {1},
pages = {1--3},
doi = {10.26524/amr.2025.2.1}
}
EUVIMED